We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Batm Advanced Communications Ld | BVC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.125 | -0.67% | 18.45 | 12:35:17 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 18.45 | 18.45 | 18.45 | 18.575 |
| Industry Sector |
|---|
| TECHNOLOGY HARDWARE & EQUIPMENT |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| 22/11/2021 | Final | GBP | 0.0074 | 09/12/2021 | 10/12/2021 | 05/01/2022 |
| Top Posts |
|---|
Posted at 19/12/2024 07:02 by wizzkid211 BATM Advanced Communications Ld New Tier 1 Customer for Edgility in MexicoThis implementation of Edgility is considered by Axtel as a first step towards providing a full suite of edge computing solutions across the enterprise market in Mexico. |
Posted at 11/12/2024 07:02 by wizzkid211 11 December 2024BATM Advanced Communications Limited ("BATM" or "the Group") Key milestone achieved with commencement of NATlab pre-clinical validation Latest phase begins at major Italian hospital following successful completion of pre-clinical trials BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, is pleased to announce that the NATlab molecular biology platform being developed by ADOR Diagnostics ("ADOR"), an associate company of the Group, has commenced pre-clinical validation at the Lazzaro Spallanzani National Institute for Infectious Diseases in Rome, Italy. This marks a key milestone in the development of NATlab and, the Group believes, will enable initial sales as well as increase industry awareness and interest from prospective partners. The advanced NATlab molecular biology platform is a point-of-care sample-to-answer solution designed to provide rapid and accurate diagnosis of infectious disease. It uses a patented isothermal amplification method for syndromic multiplex diagnostics to be able to rapidly identify a broad range of pathogens from a single test. The commencement of the pre-clinical validation phase follows the successful completion of pre-clinical trials, which were conducted at the Tzafom Medical Center in Israel, to confirm the validity of the biological process that ADOR has developed and that it can be performed within the NATlab cartridge and analyser device. NATlab identified all negative samples and had a 97% sensitivity for the positive samples, confirming the efficacy of the system and its ability to out-perform competing solutions available in the market today because of its multiplex diagnostic capability for rapid and accurate diagnosis. ADOR has now made significant progress with NATlab with the full system entering the pre-clinical validation phase at the Lazzaro Spallanzani National Institute for Infectious Diseases in Rome, a leading centre for infectious disease research and treatment. Successful completion of the pre-clinical validation is expected to enable initial sales of the NATlab and the commencement of the regulatory process under the European Union In Vitro Diagnostic Medical Device Regulation to become eligible for sale in the EU market. In addition, following the success of the pre-clinical trials, ADOR, in collaboration with the Tzafom Medical Center, has received a grant from the Israel Innovation Authority to develop a NATlab panel for the diagnosis of stomach ulcers. The total value is NIS 3.4 million (c. $1 million), which is to be granted over two years based on the achievement of milestones. Moti Nagar, Chief Executive Officer of BATM, said: "The commencement of the pre-clinical validation phase at a major European hospital is an important milestone in the development of NATlab and represents a key stage towards enabling its market entry. This also follows the successful completion of pre-clinical trials, which delivered excellent results. As the value of the substantial IP that has been built within ADOR continues to increase as well as the industry awareness of the attractiveness of the NATlab solution, we remain excited about its prospects and look forward to reporting on further progress." |
Posted at 02/12/2024 16:01 by kooba The minimum contract is denominated in us$ not £ .Anyone know what happen to this contract..over 3 years ago.Looks like a tier 1 type customer like CityFibre. It's brave getting bullish and pointing to minimum amounts even in the right currency because often with BATM you never hear about it again.3 November 2021BATM Advanced Communications Limited("BATM" or "the Group")New five-year contract for Edgility virtual networking solutionManaged service provider e -Qual selects the Group's Edgility solution to service its global enterprise customer baseBATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that its Edgility virtual networking solution has been selected by e-Qual, a managed service provider (MSP) based in France with clients in 55 countries, for the management and orchestration (MANO) of its service provision to its enterprise customers globally. The contract has a minimum period of five years and is for the Group's Edgility OS and Edgility Central products that are offered by its Telco Systems subsidiary. |
Posted at 02/12/2024 07:07 by wizzkid211 BATM Advanced Communications Ld BATM receives orders of $2.4m for Edgility |
Posted at 06/9/2024 11:53 by kemche A market professional and has so far delivered NANO, BVC, CHLL, BRSD, CHLL, ZED, ECOB, IES and a host of others. |
Posted at 28/8/2024 13:07 by kooba Oh and my comments are in no way "deceptive" i clearly state they (CEO and CFO) do not own any shares ..and have never made any market purchases ..they are not shareholders in the company they run. Thats a fact.Moti was a shareholder very briefly a few years ago (2019)when he exercised options and sold every share ( again against just about any corporate governance code i can think of ) and took a cool £1m out...maybe great foresight in dumping the lot at 46p ..obviously could find a window to deal when he wanted then !https://investing.t |
Posted at 19/8/2024 17:29 by fse "BATM Advanced Communications (LON: BVC) reported flat interim revenues due to lower revenues from networking technology, but the outlook is more positive.Cyber and diagnostics revenues grew, while networking revenues fell from $11.6m to $6m. New orders are being won in the networking division and there should be an improved second half. A new deal with Amazon should boost next year’s revenues. In the six months to June 2024, revenues dipped from $60.2m to $60m, while pre-tax profit impro..." above From UK Investor Rag. One of the unknowns here is the speed at which Edge computing solutions are getting adopted and when revenues are visible. |
Posted at 19/8/2024 11:10 by kemche BVC just cannot catch a break - if it's not Passover it's the rebalancers, or the war, or ADOR, or Cityfibre, or Zvi, or Moti, or IIs. |
Posted at 28/7/2024 12:06 by echoridge Looks like the lack of selling pressure on BVC we’ve seen in UK lately continues in Tel Aviv as the share has actually traded up on light volume so far to above the equivalent of 21p, a resistance level. Led by IES and Beeks (a huge winner over the entire year), the solid balance sheet/good value/oversold end of the small(ish) cap UK tech sector has had a solid quarter so far and I think BATM, is set to lead the group as it adds to this very quiet 30%+ recovery rally, hopefully in spite of the increase in hostilities. Even using Shore Cap’s conservative net cash position, and with no consideration of the Rome real estate, BATM is trading on just over 6x EBITDA which makes it just about the cheapest proper tech names certainly in the UK but beyond as well, even before one considers the already realised growth in Cyber and the growth potential in Networking-Edgility. Shore don’t do a half-year forecast but those results are due very soon and they will be scrutinised especially for progress in Edgility - particularly with CityFibre - and of course any update on the status of the strategic review. Still very much my share of the year despite the disappointing performance to date. |
Posted at 24/6/2024 23:32 by cumnor Agree Kooba, the CEO needs to clarify the company's current trading position, given the weird share price performance in the absence of news and the current high valuations of tech companies in the US.Moti will be aware it is more then just BVC's reputation that is being questioned here. It is Israels reputation as a country to invest in as well. Investors in Israeli companies are generally well disposed toward the country's plight in the present conflict. That could change drastically if any UK or US Israeli PLC were ever seen to be squeaky clean. BVC imo is squeaky clean. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
